Trials like TaylorX and MINDACT use genomic scores to identify patients with early-stage, HR+/HER2- breast cancer who won't benefit from adjuvant chemotherapy. This avoids significant toxicity for two-thirds to over 80% of patients who would have received it under older guidelines, without compromising their outcomes.

Advanced biomarkers are no longer just research tools. Tools like Decipher provide results within a week from a shipped sample, and Artera's MMEI simply requires scanning a pathology slide. This practicality allows clinicians to personalize treatment intensification for high-risk patients in current clinical workflows, moving beyond purely clinical risk factors.

When a patient has a BRCA2 mutation, clinicians on the panel view it as such a dominant predictive biomarker that they would prioritize a PARP inhibitor-based triplet regimen. This single genetic finding often outweighs other clinical factors or even the potential addition of docetaxel in treatment decisions.

Experts believe molecular tests like Decipher and PTEN status are superior to simply counting bone lesions for guiding treatment. While not yet standard practice for all decisions, this represents a significant shift towards using underlying tumor biology to determine therapy, like adding docetaxel.

The innovative Triple Switch trial treats all patients with a doublet therapy and then uses their PSA response at six months to guide further treatment. Patients whose PSA fails to reach a nadir are then randomized to receive docetaxel chemotherapy, testing a strategy of early intensification based on a real-time biological response rather than upfront risk stratification.

The panel suggests AKT inhibitor trials in prostate cancer have been disappointing due to suboptimal biomarker selection (e.g., PTEN IHC). A similar drug in breast cancer showed significant survival benefit when using a more precise NGS-based strategy, indicating a potential path forward if the right patient population is identified genetically.

Three 2025 trials (AMPLITUDE, PSMA-addition, CAPItello) introduced personalized therapy for metastatic hormone-sensitive prostate cancer. However, significant benefits were confined to narrow subgroups, like BRCA-mutated patients. This suggests future success depends on even more stringent patient selection, not broader application of targeted agents.

Despite guidelines and trial data suggesting low-volume patients may not benefit from chemotherapy, some oncologists offer it to a select subset. This decision is based on factors like young age, fitness, and genomic alterations in tumor suppressor genes, reflecting a personalized, biology-driven approach in an area where consensus is lacking.

For a newly diagnosed metastatic prostate cancer patient, an effective strategy is to initiate ADT alone while immediately ordering NGS testing. Waiting a few weeks for the genetic results before adding an ARPI allows for a more informed treatment choice, such as selecting a PARP inhibitor combination for a patient with a BRCA2 mutation.